Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Nvidia was the strongest force lifting the market, much as it has been throughout 2025. Stock indexes ended mixed in Europe following a stronger finish in Asia. NEW YORK (AP) — More gains for Nvidia, ...